Auro Labs.

Who are the top shareholders of the Auro Labs.?

The top shareholders of Auro Labs include Auro Impex Private Ltd with 18.75%, individual investors with 36.57%, and Kirtilaben Jayantilal Mehta as the highest public shareholder at 3.13%. There are no pledged promoter holdings or foreign institutional investors, and mutual funds hold only 0.01%.

The top shareholders of Auro Labs include the promoters, with Auro Impex Private Ltd holding the largest stake at 18.75%. Additionally, individual investors collectively own 36.57% of the company. The highest public shareholder is Kirtilaben Jayantilal Mehta, who holds 3.13%. There are no pledged promoter holdings, and the company does not have any foreign institutional investors (FIIs) involved. Mutual funds have a minimal presence, with only one scheme holding 0.01%.

Who are in the management team of Auro Labs.?

As of March 2023, the management team of Auro Labs includes Sharat Deorah (Chairman & Managing Director), Siddhartha Deorah and Kiran Kulkarni (Whole-time Directors), and several Independent Directors: Goverdhandas Aggarwal, Kailash Chandra Bubna, Kavita Vijayakant Sharma, and Vishal Kailash Chandra Jhunjhunwala, along with Sweta Agarwal (Company Secretary & Compliance Officer). This team oversees the company's operations and strategic direction.

As of March 2023, the management team of Auro Labs includes:<BR><BR>1. Sharat Deorah - Chairman & Managing Director<BR>2. Siddhartha Deorah - Whole-time Director<BR>3. Kiran Kulkarni - Whole-time Director<BR>4. Goverdhandas Aggarwal - Independent Director<BR>5. Kailash Chandra Bubna - Independent Director<BR>6. Kavita Vijayakant Sharma - Independent Director<BR>7. Vishal Kailash Chandra Jhunjhunwala - Independent Director<BR>8. Sweta Agarwal - Company Secretary & Compliance Officer<BR><BR>This team is responsible for overseeing the operations and strategic direction of the company.

What does Auro Labs. do?

Auro Laboratories Ltd is a micro-cap pharmaceutical company specializing in the production of generic Active Pharmaceutical Ingredients, particularly anti-diabetics like Metformin HCL. As of March 2025, it reported net sales of 7 Cr and a market cap of Rs 176 Cr.

Overview:<BR>Auro Laboratories Ltd is a micro-cap company in the Pharmaceuticals & Biotechnology industry, specializing in the manufacturing of generic Active Pharmaceutical Ingredients (API), particularly Anti Diabetics like Metformin HCL.<BR><BR>History:<BR>Founded in 1992, Auro Laboratories Ltd has maintained its focus on the production of generic APIs. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 7 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 176 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 115.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.59 <BR>Return on Equity: 3.69% <BR>Price to Book: 4.26 <BR><BR>Contact Details:<BR>Address: K-56 MIDC Indl Area, Tarapur Boisar Thane Maharashtra : 401506 <BR>Tel: 91-22-66635456 <BR>Email: auro@aurolabs.com <BR>Website: http://www.aurolabs.com

Has Auro Labs. declared dividend?

No Dividend History Available

Who are the peers of the Auro Labs.?

Auro Labs. peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Bal Pharma, Smruthi Organic, Aarey Drugs, and Denis Chem Lab. Auro Labs. has a good capital structure and a 1-year return of 32.94%, while its growth is below average compared to its peers.

Peers: Auro Labs. has peers including Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Bal Pharma, Smruthi Organic, Aarey Drugs, and Denis Chem Lab.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Smruthi Organic, and Quest, while Average management risk is found at Bal Pharma, Aarey Drugs, and Denis Chem Lab. Growth is excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while below average growth is noted for Divi's Lab., Torrent Pharma, Auro Labs., Smruthi Organic, Bal Pharma, Aarey Drugs, and Denis Chem Lab. Capital structure is excellent for Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs., and Smruthi Organic, while good capital structure is found at Torrent Pharma and Auro Labs., and below average capital structure is noted for Bal Pharma, Aarey Drugs, and Denis Chem Lab.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.69%, while Bal Pharma has the lowest at -15.30%. Auro Labs.'s 1-year return of 32.94% is significantly higher than Bal Pharma's. Additionally, the six-month return is negative for Bal Pharma, Smruthi Organic, and Denis Chem Lab.

Is Auro Labs. overvalued or undervalued?

As of February 17, 2025, Auro Labs is considered very expensive and overvalued, with a PE Ratio of 113.15 and an EV to EBITDA of 60.60, significantly higher than its peers, despite a recent 1-year stock return of 35.93% compared to the Sensex's 7.60%.

As of 17 February 2025, Auro Labs has moved from an expensive to a very expensive valuation grade. The company is currently overvalued based on its financial metrics. Key ratios include a PE Ratio of 113.15, an EV to EBITDA of 60.60, and a Price to Book Value of 4.18, which significantly exceed those of its peers. For instance, Sun Pharma has a PE Ratio of 35.25 and an EV to EBITDA of 24.91, while Divi's Lab shows a PE of 79.33 and an EV to EBITDA of 57.35, both indicating that Auro Labs is trading at a premium compared to these competitors.<BR><BR>In addition to its high valuation ratios, Auro Labs has a ROCE of 8.79% and a ROE of 3.69%, which do not justify its elevated price levels. The company has outperformed the Sensex in recent periods, with a 1-year stock return of 35.93% compared to the Sensex's 7.60%, yet this strong performance does not mitigate the overvaluation indicated by its financial ratios.

What is the technical trend for Auro Labs.?

As of May 13, 2025, Auro Labs has shifted to a bullish trend with strong indicators, including bullish MACD and Bollinger Bands on both weekly and monthly time frames, despite a mildly bearish KST signal, and has outperformed the Sensex with a 10.98% gain over the past week and 19.19% over the past month.

As of 13 May 2025, the technical trend for Auro Labs has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The MACD is bullish on both the weekly and monthly time frames, and Bollinger Bands also indicate a bullish trend on both time frames. The daily moving averages are bullish, reinforcing the positive outlook. However, the KST shows a mildly bearish signal on the monthly, and Dow Theory indicates a mildly bullish stance on the monthly with no trend on the weekly. Overall, the strength of the bullish trend is supported by the recent price action, with the stock returning 10.98% over the past week and 19.19% over the past month, significantly outperforming the Sensex.

How big is Auro Labs.?

As of 24th July, Auro Laboratories Ltd has a market capitalization of 172.00 Cr, with recent net sales of 19.27 Cr and a net profit of 1.55 Cr. The company reported shareholder's funds of 41.96 Cr and total assets of 85.73 Cr for the annual period ending March 2024.

As of 24th July, Auro Laboratories Ltd has a market capitalization of 172.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Auro Laboratories reported Net Sales of 19.27 Cr and a Net Profit of 1.55 Cr.<BR><BR>For the latest annual period ending March 2024, the company had Shareholder's Funds amounting to 41.96 Cr and Total Assets of 85.73 Cr.

How has been the historical performance of Auro Labs.?

Auro Labs reported a net profit of 1.84 crore and total operating income of 19.40 crore for the year ending March 2025, with a profit after tax margin of 9.48% and an operating profit margin of 17.58%. Total liabilities increased to 99.10 crore, driven by long-term borrowings of 30.79 crore, while shareholder's funds grew to 42.97 crore.

Answer:<BR>The historical performance of Auro Labs shows a consolidated net profit of 1.84 crore for the year ending March 2025, with total operating income of 19.40 crore. The operating profit margin, excluding other income, stands at 17.58%, while the profit after tax margin is 9.48%. The company has total liabilities of 99.10 crore, with long-term borrowings increasing significantly to 30.79 crore from previous years. The total assets have also risen to 99.10 crore, reflecting growth in shareholder's funds, which reached 42.97 crore. <BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Auro Labs reported a total operating income of 19.40 crore, with a net profit of 1.84 crore, indicating a profit after tax margin of 9.48%. The operating profit, excluding other income, was 3.41 crore, leading to an operating profit margin of 17.58%. The company's total liabilities increased to 99.10 crore, driven by a rise in long-term borrowings to 30.79 crore. Shareholder's funds grew to 42.97 crore, supported by total reserves of 36.74 crore. The total assets also saw an increase, reaching 99.10 crore, while the cash flow from operating activities was reported at 5.00 crore, reflecting a net cash outflow of 1.00 crore for the year.

Are Auro Laboratories Ltd latest results good or bad?

Auro Laboratories Ltd's latest Q2 FY26 results show a significant operational turnaround with a net profit of ₹0.72 crore and a 219.13% revenue increase. However, long-term challenges like declining sales, low return on equity, and a high P/E ratio suggest caution for investors.

Auro Laboratories Ltd's latest results for Q2 FY26 indicate a significant operational turnaround, showcasing both positive and concerning aspects. The company reported a net profit of ₹0.72 crore, marking a recovery from a loss in the previous quarter. Additionally, revenue surged by 219.13% quarter-on-quarter to ₹8.84 crore, which is a remarkable improvement.<BR><BR>The operating margin also improved dramatically to 26.70%, up from just 0.72% in Q1 FY26, reflecting better cost management and operational efficiency. However, despite these positive indicators, the company faces serious long-term challenges, including a five-year sales decline of -13.87% annually and a concerning return on equity (ROE) of only 10.30%, which is below the industry average.<BR><BR>Moreover, the company's high P/E ratio of 157.30x raises questions about its valuation, especially given the structural issues it faces. The elevated debt levels and minimal institutional interest further complicate the outlook.<BR><BR>In summary, while the latest quarterly results show a strong recovery, the underlying structural challenges and high valuation suggest caution for investors.

When is the next results date for Auro Laboratories Ltd?

The next results date for Auro Laboratories Ltd is 29 May 2026.

The next results date for Auro Laboratories Ltd is scheduled for 29 May 2026.

Why is Auro Laboratories Ltd falling/rising?

As of 02-Jun, Auro Laboratories Ltd's stock price is at 266.95, down 0.26% after two consecutive days of decline totaling 3.8%. Despite a positive long-term performance, recent trends indicate short-term weakness due to decreased investor participation and positioning below the 5-day moving average.

As of 02-Jun, Auro Laboratories Ltd's stock price is currently at 266.95, reflecting a decrease of 0.7, or 0.26%. The stock has been experiencing a decline, having fallen consecutively for the last two days, resulting in a total drop of 3.8% during this period. Additionally, the stock's performance over the past week shows a slight decrease of 0.06%, while the benchmark Sensex has decreased by 1.79%, indicating that Auro Laboratories has outperformed the benchmark slightly in this timeframe.<BR><BR>Despite a positive performance over the longer term, with a 1-month increase of 11.65% and a year-to-date increase of 7.02%, the recent trend suggests a downturn. This decline is compounded by a significant drop in investor participation, as evidenced by a 64.35% decrease in delivery volume compared to the 5-day average. Furthermore, while the stock is trading above its 20-day, 50-day, 100-day, and 200-day moving averages, it is below its 5-day moving average, which may indicate short-term weakness.<BR><BR>Overall, the combination of recent consecutive losses, reduced investor participation, and the stock's current positioning relative to its moving averages contributes to the observed decline in Auro Laboratories Ltd's stock price.

Which are the latest news on Auro Labs.?

Should I buy, sell or hold Auro Laboratories Ltd?